Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-02 20:36 | 2026-04-02 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $565.87 | 8,300 | $4,696,690 | 45,172 |
| 2026-04-02 17:01 | 2026-04-01 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | Officer | OPT+S | $32.31 | 28,662 | $926,095 | 9,597 |
| 2026-04-02 16:00 | 2026-03-31 | KRRO | Korro Bio, Inc. | Lynx1 Capital Management LP | 10% owner | BUY | $10.60 | 520 | $5,512 | 1,538,296 |
| 2026-04-02 12:01 | 2026-04-01 | SCYX | SCYNEXIS INC | Angulo Gonzalez David | Director, Officer | BUY | $0.00 | 108,695 | $0 | 1,357,126 |
| 2026-04-01 21:08 | 2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Bigora Sian | Officer | BUY | $2.54 | 2,107 | $5,341 | 3,711 |
| 2026-04-01 20:27 | 2026-03-30 | DYN | Dyne Therapeutics, Inc. | Posner Brian S | Director | BUY | $17.08 | 2,000 | $34,160 | 15,500 |
| 2026-04-02 01:28 | 2026-03-30 | ANAB | ANAPTYSBIO, INC | Schmid John P. | Director | SELL | $56.11 | 20,645 | $1,158,451 | 31,622 |
| 2026-04-02 00:00 | 2026-03-31 | CAPR | CAPRICOR THERAPEUTICS, INC. | Bergmann Anthony | Officer | OPT+S | $30.13 | 25,000 | $753,153 | 8,223 |
| 2026-04-02 00:00 | 2026-03-31 | CAPR | CAPRICOR THERAPEUTICS, INC. | Sabar Karimah Es | Director | OPT+S | $30.57 | 115,000 | $3,515,470 | 0 |
| 2026-04-02 00:00 | 2026-03-31 | CAPR | CAPRICOR THERAPEUTICS, INC. | Krasney Karen | Officer | OPT+S | $30.12 | 25,000 | $752,935 | 30,547 |
| 2026-04-01 22:58 | 2026-04-01 | ALKS | Alkermes plc. | Hopkinson Craig C. | Officer | OPT+S | $35.51 | 9,000 | $319,604 | 85,389 |
| 2026-04-01 21:54 | 2026-03-30 | XERS | Xeris Biopharma Holdings, Inc. | Brady James Aloysius | Director | SELL | $5.54 | 10,834 | $60,036 | 89,166 |
| 2026-04-01 21:26 | 2026-03-31 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Soteropoulos Paula | Director | OPT+S | $80.11 | 599 | $47,986 | 0 |
| 2026-04-01 21:26 | 2026-03-31 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Savitz Ryan | Officer | OPT+S | $83.00 | 114,367 | $9,492,598 | 0 |
| 2026-04-01 21:09 | 2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Guy Wendy | Officer | BUY | $2.54 | 1,854 | $4,700 | 3,110 |
| 2026-04-01 21:10 | 2026-04-01 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% owner | SELL | $4.97 | 4,278 | $21,262 | 426,816 |
| 2026-04-01 21:11 | 2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Lin Patrick | Officer | BUY | $2.54 | 1,603 | $4,064 | 3,356 |
| 2026-04-01 21:15 | 2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Ng George K | Director, Officer | BUY | $2.54 | 2,136 | $5,415 | 3,649 |
| 2026-04-01 21:17 | 2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Pannu Geraldine | Director | BUY | $2.54 | 2,072 | $5,253 | 2,188 |
| 2026-04-01 21:18 | 2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | SKIBSTED RUSSELL | Officer | BUY | $2.54 | 2,324 | $5,891 | 2,324 |
| 2026-04-01 21:20 | 2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Young David | Director, Officer | BUY | $2.54 | 1,810 | $4,588 | 10,562 |
| 2026-04-01 21:06 | 2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Baluch Khoso | Director | BUY | $2.54 | 2,269 | $5,752 | 2,325 |
| 2026-04-01 20:30 | 2026-03-31 | CNTB | Connect Biopharma Holdings Ltd | Huang James | Director | BUY | $3.45 | 1,160,000 | $4,002,000 | 13,160,000 |
| 2026-04-01 20:30 | 2026-03-31 | ZBIO | Zenas BioPharma, Inc. | Fairmount Funds Management LLC | Director | BUY | $20.00 | 150,000 | $3,000,000 | 2,359,025 |
| 2026-04-01 20:30 | 2026-03-30 | NUVL | Nuvalent, Inc. | Noci Darlene | Officer | OPT+S | $97.81 | 5,500 | $537,942 | 58,117 |
| 2026-04-01 20:34 | 2026-04-01 | CYTK | CYTOKINETICS INC | Blum Robert I | Director, Officer | SELL | $66.63 | 7,500 | $499,725 | 422,830 |
| 2026-04-01 20:05 | 2026-04-01 | ALT | Altimmune, Inc. | Durso Jerome Benedict | Director, Officer | BUY | $3.14 | 15,000 | $47,100 | 47,500 |
| 2026-04-01 20:05 | 2026-04-01 | ALT | Altimmune, Inc. | WEAVER GREGORY L | Officer | BUY | $3.15 | 10,000 | $31,499 | 38,078 |
| 2026-04-01 20:05 | 2026-03-30 | PVLA | PALVELLA THERAPEUTICS, INC. | JENKINS GEORGE M | Director | BUY | $112.30 | 445 | $49,974 | 187,616 |
| 2026-04-01 13:31 | 2026-03-31 | TNXP | Tonix Pharmaceuticals Holding Corp. | LEDERMAN SETH | Director, Officer | BUY | $12.62 | 5,000 | $63,100 | 20,001 |
| 2026-04-01 11:31 | 2026-03-31 | NSRX | Nasus Pharma Ltd | Teleman Dan Benjamin | Director, Officer | BUY | $2.04 | 15,000 | $30,600 | 21,246 |
| 2026-03-31 20:10 | 2026-03-27 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Bozic Carmen | Officer | SELL | $450.95 | 2,329 | $1,050,263 | 33,076 |
| 2026-03-31 20:25 | 2026-03-30 | ASMB | ASSEMBLY BIOSCIENCES, INC. | Bjorkquist Jeanette M | Officer | SELL | $26.69 | 328 | $8,755 | 11,089 |
| 2026-03-31 20:15 | 2026-03-27 | MLYS | Mineralys Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | BUY | $23.75 | 369,000 | $8,762,791 | 5,825,521 |
| 2026-03-31 20:13 | 2026-03-30 | INSM | INSMED Inc | Smith Michael Alexander | Officer | OPT+S | $150.98 | 19,638 | $2,964,945 | 51,871 |
| 2026-03-31 20:10 | 2026-03-30 | PGEN | PRECIGEN, INC. | KIRK RANDAL J | Director, 10% owner | SELL | $3.30 | 4,772,781 | $15,750,177 | 12,262,741 |
| 2026-04-01 01:30 | 2026-03-31 | COGT | Cogent Biosciences, Inc. | Fairmount Funds Management LLC | Director | SELL | $34.66 | 7,000,000 | $242,620,000 | 5,503,418 |
| 2026-04-01 01:03 | 2026-03-31 | ABEO | ABEONA THERAPEUTICS INC. | Seshadri Vishwas | Director, Officer | SELL | $4.38 | 29,985 | $131,481 | 1,430,423 |
| 2026-04-01 00:14 | 2026-03-30 | ZBIO | Zenas BioPharma, Inc. | MOULDER LEON O JR | Director, Officer | BUY | $18.91 | 54,000 | $1,021,140 | 1,726,039 |
| 2026-04-01 00:15 | 2026-03-27 | SLNO | SOLENO THERAPEUTICS INC | Huang Michael F. | Officer | SELL | $30.44 | 6,582 | $200,365 | 39,823 |
| 2026-04-01 00:17 | 2026-03-27 | SLNO | SOLENO THERAPEUTICS INC | Manning Meredith | Officer | SELL | $30.44 | 7,522 | $228,979 | 64,507 |
| 2026-03-31 23:33 | 2026-03-31 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | Officer | OPT+S | $32.12 | 21,338 | $685,308 | 9,597 |
| 2026-03-31 22:44 | 2026-03-30 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $53.75 | 14,080 | $756,834 | 38,120 |
| 2026-03-31 21:53 | 2026-03-06 | LGND | LIGAND PHARMACEUTICALS INC | LAMATTINA JOHN L | Director | OPT+S | $200.76 | 2,161 | $433,842 | 30,724 |
| 2026-03-31 20:59 | 2026-03-30 | RZLT | Rezolute, Inc. | Evans Daron | Officer | BUY | $2.85 | 10,000 | $28,500 | 414,462 |
| 2026-03-31 21:00 | 2026-03-31 | ZBIO | Zenas BioPharma, Inc. | Lu Hongbo | Director | BUY | $20.00 | 75,000 | $1,500,000 | 422,968 |
| 2026-03-31 20:27 | 2026-03-30 | RAPP | Rapport Therapeutics, Inc. | Gault Cheryl | Officer | SELL | $28.19 | 10,000 | $281,857 | 159,914 |
| 2026-03-31 20:31 | 2026-03-27 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $526.96 | 9,500 | $5,006,099 | 40,513 |
| 2026-03-31 20:31 | 2026-03-30 | UTHR | UNITED THERAPEUTICS Corp | CAUSEY CHRISTOPHER | Director | OPT+S | $604.64 | 1,300 | $786,032 | 4,190 |
| 2026-03-31 20:32 | 2026-03-30 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $593.17 | 10,000 | $5,931,683 | 18,876 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.